Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D, AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials

医学 不利影响 杜拉鲁肽 安慰剂 二甲双胍 糖尿病 内科学 2型糖尿病 随机对照试验 内分泌学 胃肠病学 药理学 艾塞那肽 替代医学 病理
作者
Vanita R. Aroda,Juan P. Frías,Linong Ji,Elisabeth Niemoeller,My‐Liên Nguyên‐Pascal,Karl Denkel,Melanie Espinasse,Hailing Guo,Seung Jae Baek,JaeDuk Choi,Ildiko Lingvay
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:25 (8): 2084-2095 被引量:4
标识
DOI:10.1111/dom.15079
摘要

Abstract Aim To evaluate the efficacy and safety of once‐weekly (QW) efpeglenatide in people with type 2 diabetes (T2D) suboptimally controlled with oral glucose‐lowering drugs and/or basal insulin (BI). Materials and Methods Three phase 3, multicentre, randomized controlled trials compared the efficacy and safety of QW efpeglenatide versus dulaglutide when added to metformin (AMPLITUDE‐D), efpeglenatide versus placebo when added to BI ± oral glucose‐lowering drugs (AMPLITUDE‐L) or metformin ± sulphonylurea (AMPLITUDE‐S). All trials were terminated early by the sponsor because of funding rather than safety or efficacy concerns. Results In AMPLITUDE‐D, non‐inferiority of efpeglenatide to dulaglutide 1.5 mg was shown in HbA1c reduction from baseline to week 56, least squares mean treatment difference (95% CI): 4 mg, −0.03% (−0.20%, 0.14%)/−0.35 mmol/mol (−2.20, 1.49); 6 mg, −0.08% (−0.25%, 0.09%)/−0.90 mmol/mol (−2.76, 0.96). The reductions in body weight (approximately 3 kg) from baseline to week 56 were similar across all treatment groups. In AMPLITUDE‐L and AMPLITUDE‐S, numerically greater reduction in HbA1c and body weight were observed at all doses of efpeglenatide than placebo. American Diabetes Association level 2 hypoglycaemia (< 54 mg/dL [< 3.0 mmol/L]) was reported in few participants across all treatment groups (AMPLITUDE‐D, ≤ 1%; AMPLITUDE‐L, ≤ 10%; and AMPLITUDE‐S, ≤ 4%). The adverse events profile was consistent with other glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs); gastrointestinal adverse events were most frequent in all three studies. Conclusions In people with T2D suboptimally controlled with oral glucose‐lowering drugs and/or BI, QW efpeglenatide was non‐inferior to dulaglutide in terms of HbA1c reduction and showed numerically greater improvements than placebo in glycaemic control and body weight, with safety consistent with the GLP‐1 RA class.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
学术大拿特拿完成签到,获得积分10
1秒前
sci发布了新的文献求助10
1秒前
李洁完成签到,获得积分10
1秒前
1秒前
1秒前
Suki完成签到 ,获得积分10
2秒前
悦耳的海秋完成签到 ,获得积分10
2秒前
隐形曼青的应助被肖孟良采纳,获得10
3秒前
科研通AI6.3的应助被紫葡萄采纳,获得10
3秒前
molihuakai的应助被杨某某采纳,获得10
4秒前
小任一定行完成签到,获得积分20
4秒前
4秒前
zzm发布了新的文献求助10
4秒前
鳗鱼元风的应助被maocai0306采纳,获得10
4秒前
冷艳的紫发布了新的文献求助10
4秒前
哈哈完成签到,获得积分10
5秒前
爱笑的安寒完成签到 ,获得积分10
5秒前
5秒前
FashionBoy的应助被星河采纳,获得10
5秒前
6秒前
6秒前
daomaihu发布了新的文献求助100
6秒前
7秒前
7秒前
7秒前
ak完成签到,获得积分10
8秒前
思源的应助被阿哲采纳,获得10
8秒前
一二三完成签到,获得积分10
8秒前
sci完成签到,获得积分10
8秒前
8秒前
10秒前
10秒前
10秒前
11秒前
11秒前
xx发布了新的文献求助10
12秒前
盒子发布了新的文献求助10
12秒前
13秒前
摸鱼大王发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177135
求助须知:如何正确求助?哪些是违规求助? 9568196
关于积分的说明 21797695
捐赠科研通 7771894
什么是DOI,文献DOI怎么找? 3432251
关于科研通互助平台的介绍 2556506
邀请新用户注册赠送积分活动 2477791